CytomX presents Varseta-M development plan targeting registrational study start in first half of 2027
CTMX•CytomX targets a registrational study of Varseta-M in relapsed or refractory metastatic colorectal cancer in the first half of 2027. Confirmed objective response rates were 20% and 32% at two doses, while cash totaled $348 million as of the third quarter of 2026.
1. Development timeline
CytomX Therapeutics targets a registrational study of Varseta-M in relapsed or refractory metastatic colorectal cancer in the first half of 2027. A Phase 1/2 trial combining Varseta-M with bevacizumab and chemotherapy is planned to begin by year-end 2026.
2. Trial results and cash
In late-line colorectal cancer, confirmed objective response rates reached 20% at 8.6 mg/kg and 32% at 10 mg/kg. Preliminary progression-free survival was 6.8 months and 7.1 months, respectively. Cash totaled $348 million as of the third quarter of 2026, providing runway into the second half of 2028.
